drugset

drugset / Trial / NCT00242827

Efficacy and Safety of Oral CEP-701 for the Treatment of Patients With Advanced Multiple Myeloma

NCT00242827 ↗

Phase 2 Terminated Cephalon

Non-randomizedCrossoverOpen-labelTreatment

Summary

An Open-Label Study of the Efficacy and Safety of Oral CEP-701 for the Treatment of Patients with Advanced Multiple Myeloma.

Timeline

Start: 2006-04
Primary completion: —
Completion: 2007-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	lestaurtinib	Small molecule	—	Oral

Indications